时间：2015-05-07 08:00:00 至 2015-05-08 18:00:00
该会议暂无费用信息，您可以点击 "我要咨询" 会议有更新我们将通知您。
Due to declining research and development productivity, stringent regulatory activities and generic competition for off patent product, the traditional pharma industry is stagnant. On the contrary, biopharma industry (which mainly refers to antibody and vaccine) has developed as highly profitable because of advancements in genomics and manufacturing technologies as well as increasing demand from emerging economies. It is estimated that the global sales revenue of biotech drugs will account for more than one-third of all kinds of drug sales by 2020. China's biopharma market is expected to reach 100 billion US dollars by 2015.
Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2013, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. In 2013-2017, the mab market size will hit USD141 billion in 2017 in which Chinese monoclonal antibody market is predicted grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012). Meanwhile in the last 2 years, biobetters and ADCs are gaining increasing global attention due to its superior performance. Many of the Asian mAb biosimilar developers have also turned their interests to biobetter development.
Looking into global vaccine market, the market, which stood at US$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.
In recognition of fast growing biopharma market in Asia and increasing volume of technology transfer and licensing deals happening in Asia to drive the biopharma innovation, Global Vaccine and Antibody China Summit 2015 (GVAC 2015) will convene in Shanghai in May. It is the premier international summit of its kind in China to cover the whole value chain of biologics industry from Biosimilars and Biobetters, BioProcessing, BioAnalytical to BioPartnerships and Therapeutic Vaccines. GVAC 2015 will draw 200+ top antibody and vaccine leaders from global together with experts from biotech, clinical trials, gene engineering, antibody engineering, cell cultures, and related products and technologies to explore innovation and partnership opportunities in biopharma industry in Asia. Built upon the long-standing and successful organization of Vaccine Forum in China over the years, GVAC delivers a unique new networking concept, combining unparallel learning and partnering opportunities for the global industry players, manufacturing and R&D executive, plus key external stakeholders including NGOs and public and private sector investors to brainstorm how to bring the vibrant China’s and Asian biopharma market to the next level. We look forward to seeing you in May, 2015 in Shanghai, China.
We look forward to seeing you in Shanghai!
Who Should Attend
• Biopharmaceuticals (Vaccines, Antibodies, Biosimilars, Therapeutic Proteins)
• Cell Culture
• Bioprocessing Equipments
• Research Technology and Equipments
• Cold Chain
• Packaging Technology and Equipments
• Facility Design and Construction
• Academia / Research Institutes
Targeted Job Titles
President, CEOs, CSOs, Vice Presidents, Medical Directors, Managers and Heads of:
• Business Development / Marketing
• Research and Development
• Clinical Development
• Regulatory Affairs
• Strategic Product Development
• Manufacturing/Production Technology
• Quality Assurance/Quality Control
• Process Development
• Supply Outsourcing
• Project Management